Loading...
OTC Markets
Totals
Securities
12,266
Dollar Vol
$3.0B
Share Vol
4.8B
Trades
409,199

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

Zelira Therapeutics Ltd. Company Logo

ZLDAF
Zelira Therapeutics Ltd.

Ordinary Shares

0.21

0.00

0.00%

0.1814 / 0.2389 (5000 x 2500)

Real-Time Best Bid & Ask: 05:00pm 11/17/2025
Delayed (15 Min) Trade Data: 12:00am 11/12/2025

0.00

N/A

0

Market Cap calculated only for this class of securities.

2,498,403

Real-Time Level 2 Quote
Trade Data
News
Company Description
Zelira Therapeutics Ltd. Company Logo
Zelira Therapeutics Ltd is a leading global biopharmaceutical company in the research, development and commercialisation of clinically validated cannabinoid-based medicines. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development positioned to enter global markets. The Company is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions including insomnia, autism and chronic non-cancer pain as well as offering over the counter (OTC) products
Videos
OTCQB Venture Market Logo
Venture Market
The Company Profile data was verified by the issuer within the previous 6 months.
This company has certified to OTC Markets Group that it is eligible to rely on the exemption from registration under Securities and Exchange Act Rule 12g3-2(b).
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.